7561 Stock Overview
Engages in the research and development, manufacture, and sale of biological and health supplement products. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Bioray Biotech Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$20.50 |
| 52 Week High | NT$33.15 |
| 52 Week Low | NT$18.50 |
| Beta | 0.28 |
| 11 Month Change | -5.09% |
| 3 Month Change | -21.15% |
| 1 Year Change | -26.92% |
| 33 Year Change | -57.91% |
| 5 Year Change | n/a |
| Change since IPO | -71.76% |
Recent News & Updates
Shareholder Returns
| 7561 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -1.7% | -2.5% | -0.5% |
| 1Y | -26.9% | 0.7% | 28.4% |
Return vs Industry: 7561 underperformed the TW Biotechs industry which returned 2% over the past year.
Return vs Market: 7561 underperformed the TW Market which returned 29% over the past year.
Price Volatility
| 7561 volatility | |
|---|---|
| 7561 Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 4.5% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.1% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 7561 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 7561's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | n/a | n/a | www.bio-ray.com.tw |
Bioray Biotech Co., Ltd engages in the research and development, manufacture, and sale of biological and health supplement products. Its biological products include functional probiotics, medicinal fungi, and immune cell preparations. The company is also involved in the cell testing and storage business.
Bioray Biotech Co., Ltd Fundamentals Summary
| 7561 fundamental statistics | |
|---|---|
| Market cap | NT$611.58m |
| Earnings (TTM) | -NT$15.80m |
| Revenue (TTM) | NT$183.57m |
3.3x
P/S Ratio-38.7x
P/E RatioIs 7561 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7561 income statement (TTM) | |
|---|---|
| Revenue | NT$183.57m |
| Cost of Revenue | NT$115.97m |
| Gross Profit | NT$67.59m |
| Other Expenses | NT$83.39m |
| Earnings | -NT$15.80m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.53 |
| Gross Margin | 36.82% |
| Net Profit Margin | -8.61% |
| Debt/Equity Ratio | 8.4% |
How did 7561 perform over the long term?
See historical performance and comparison